The Premenopausal Breast Cancer Collaborative Group IMPORTANCE The association between increasing body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer epidemiology in that a crossover effect exists, with risk reduction before and risk increase after menopause. The inverse association with premenopausal breast cancer risk is poorly characterized but might be important in the understanding of breast cancer causation. OBJECTIVE To investigate the association of BMI with premenopausal breast cancer risk, in particular by age at BMI, attained age, risk factors for breast cancer, and tumor characteristics.
B reast cancer is the most commonly diagnosed cancer among women worldwide, accounting for 25% of female cancer cases at all ages and a greater percentage among young women. 1 Its complex etiology involves an unusually large range of factors, of which adiposity, often assessed as body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), is important and appears to have opposing effects at premenopausal and postmenopausal ages.
Increased adiposity in childhood and before menopause has been reported to be inversely associated with the risk of breast cancer diagnosed at premenopausal and postmenopausal ages, whereas increased adiposity after menopause is positively associated with risk. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, because incidence rates are lower among premenopausal than postmenopausal women, individual studies have had limited ability to investigate the association of BMI with the risk of premenopausal breast cancer. Past studies have been case-control studies, with potential for bias, and most prospective studies have had modest numbers of cases, except for some recent studies in Asian 12, 13 or Jewish Israeli 14 populations, but have not assessed risk at different ages, by tumor type, and by menopausal status at breast cancer diagnosis. Meta-analyses have aggregated studies that differed in age at BMI assessment, attained age of participants, and degree of adjustment for potential confounding, and results were not stratified by other risk factors. [2] [3] [4] [5] [15] [16] [17] [18] Some studies suggest that the association of premenopausal adiposity with risk varies by tumor characteristics, 2, 7, [17] [18] [19] but larger studies are needed to provide stable estimates by hormone receptor status or intrinsic tumor subtype.
To undertake a more powerful and systematic analysis of the association of BMI with breast cancer risk in premenopausal women, we pooled individual-level data from 758 592 women, including 13 082 cases of breast cancer, from 19 prospective cohort studies using data from recruitment and follow-up questionnaires. We aimed to estimate the relative risk associated with BMI at different ages, age at breast cancer diagnosis, and breast cancer characteristics and to explore whether associations were modified by other risk factors for breast cancer.
Methods
Information on the Premenopausal Breast Cancer Collaborative Group, a collaboration facilitated by the National Cancer Institute Cohort Consortium, has been published previously. 20 In short, individual-level data were pooled from 19 prospective cohorts in North America (n = 9), Europe (n = 7), Asia (n = 2), and Australia (n = 1), 20 with participants recruited from January 1, 1963 1, , through December 31, 2013 and at least 100 breast cancer cases diagnosed before 55 years of age. Data were harmonized to a common template for 1 to 16 questionnaire rounds per study. Full details of the study cohorts are given in the eMethods in the Supplement. All contributing studies gained approval from institutional review boards and obtained consent from participants as per country-specific requirements.
We used information on self-reported or measured current weight and height from multiple questionnaire rounds and information reported on questionnaires about weight at ages before study entry to construct BMI within the age ranges of 18 to 24, 25 to 34, 35 to 44, and 45 to 54 years. We categorized BMI according to World Health Organization definitions. 21 The analysis included all participants who were premenopausal, had no personal history of breast cancer at study entry, and had data for premenopausal BMI available.
All breast cancers included in this analysis occurred before menopause, with the main analytic end point being invasive or in situ premenopausal breast cancer overall. However, we also analyzed separately by invasive and in situ cancer, by immunohistochemistry data on estrogen receptor (ER) and progesterone receptor (PR) status, and by clinicopathologic surrogate definitions of intrinsic breast cancer subtype.
Hazard ratios (HRs) were obtained as estimates of the relative risk of breast cancer from Cox proportional hazards regression models 22 with attained age as the underlying timescale. Follow-up for breast cancer started at study entry or the age after enrollment to which the BMI applied. Follow-up ended at breast cancer diagnosis, menopause (or hysterectomy), last follow-up, death, or age 55 years, whichever occurred first.
We first generated cohort-specific relative risk estimates and obtained a pooled estimate with a 2-stage model. 23 Because no appreciable between-study heterogeneity was detected using the I 2 statistic, 24 the data were analyzed in a pooled data set. All presented analyses were adjusted for attained age (implicit in the Cox proportional hazards regression model), cohort, year of birth, age at menarche, age at first birth, time since last birth, parity, and family history of breast cancer. Covariate information was time updated, when possible, with information from follow-up questionnaires.
We analyzed BMI separately as categorical and continuous variables (per 5 kg/m 2 [5.0-U] difference), assuming a loglinear dose-response association, the validity of which was checked using restricted cubic spline models. 25 We tested for effect modification by other risk factors for breast cancer and by attained age using log-likelihood ratio tests. 26 Analyses by breast tumor subtype were conducted using an augmentation method. 27 This method allows estimation of separate risk factor associations for type-specific outcomes in a single model stratified on outcome type, obtained from a data set in which separate observations on each participant have been created for each outcome. Conducted sensitivity analyses are outlined in the eMethods in the Supplement. We used Stata, version 14. 2 (StataCorp) for all analyses, with P < .05 indicating signficance. 28 
Results
The analyses included 758 592 women (median age, 40.6 years; interquartile range, 35. 2-45.5 years) , among whom 13 082 in situ or invasive breast cancer cases occurred during 7.2 million premenopausal years of follow-up (median, 9.3 years; interquartile range, 4.9-13.5 years) (eTable 1 in the Supplement). Weight was provided at 1 to 14 (median, 2) follow-up rounds per study and was self-reported for 88.9% to 99.6% of weights, depending on age. Weight at ages 18 to 24 years was retrospectively reported for 96.9% and at later ages for less than 10% of women. Obesity (BMI≥30.0) was more common in women who were 45 years or older (11.1%), were nulliparous (12.4%), had an early menarche (17.0%), had a family history of breast cancer (12.8%), or were black (26.8%) (Table) .
Increasing BMI was linearly associated with decreasing risk of breast cancer in the restricted cubic spline models (eFigures 1 and 2 in the Supplement), except that, for some ages and tumor types, there appeared to be a leveling of risk for underweight women (BMI<18.5) compared with those in the normal weight range (BMI, ). We therefore restricted the linear modeling of BMI to values of 18.5 or greater.
Hazard ratios for breast cancer decreased with increasing BMI category (Figure 1) , more for BMI at younger than older ages, with a risk reduction of 23% per 5.0-U difference (HR, 0.77; 95% CI, 0.73-0.80) for BMI at ages 18 to 24 years and 12% (HR, 0.88; 95% CI, 0.86-0.91) for BMI at 45 to 54 years. The risk gradient was 4.2-fold between the highest and lowest BMI categories (BMI≥35.0 vs <17.0) at ages 18 to 24 years (HR, 0.24; 95% CI, 0.14-0.40). Significant differences in relative risk were present even within the normal range of BMI (for 23.0-24.9 vs 18. 5-22.9 : HR, 0.80; 95% CI, 0.75-0.86). The HRs for BMI at ages 18 to 24 years remained statistically significant after additional adjustment for most recent BMI (HR per 5.0-U increase, 0.80; 95% CI, 0.76-0.84). We found no appreciable heterogeneity in the association between studies (eFigure 3A-D in the Supplement).
Weight at ages 18 to 24 years was correlated with weights at older ages (r = 0.70 for ages 25-34, r = 0.63 for ages 35-44, and r = 0.55 for ages 45-54 years). When we adjusted the analyses of breast cancer risk in Figure 2 for BMI at ages 18 to 24 years, the HRs per 5.0-U increase were 0.92 (95% CI, 0.88-0.97) for BMI at ages 25 to 34 years, 0.93 (95% CI, 0.91-0.96) at ages 35 to 44 years, and 0.91 (95% CI, 0.88-0.95) at ages 45 to 54 years ( Figure 2 and eTable 2 in the Supplement). The magnitude of the inverse associations was similar between categories of attained age to age 55 years (eFigure 4 in the Supplement).
Incident cases of breast cancer included 10 836 invasive and 2138 in situ breast cancers. Associations with risk per 5.0-U difference in BMI were significantly larger for in situ (HR, 0.76; 95% CI, 0.69-0.85) than for invasive breast cancer (HR, 0.88; 95% CI, 0.84-0.92) (P = .02 for interaction) for BMI at ages 25 to 34 years; difference in associations were also found for in situ (HR, 0.81; 95% CI, 0.76-0.86) and invasive breast cancer (HR, 0.88; 95% CI, 0.86-0.90; P =. 01for interaction) at 35 to 44 years (eTable 3 in the Supplement). The percentage of all breast cancers that were in situ did not appreciably vary by BMI, and women with higher BMI were more likely to have had a screening mammogram (eTable 4 in the Supplement).
The ER and/or PR status was known for 7812 cases, 7002 (89.6%) of which were invasive. We did not observe consistent significant differences in HRs for ER-positive vs ERnegative or PR-positive vs PR-negative breast cancer (eTable 5intheSupplement). When considering ER and PR jointly, ER-positive and/or PR-positive breast cancer showed stronger associations with BMI at ages 18 to 24 years (eg, for ERpositive and PR-positive, HR, 0.75; 95% CI, 0.70-0.81) than did hormone receptor-negative breast cancer; however, the association was still significant for ER-negative and PR-negative breast cancer (HR, 0.85; 95% CI, 0.76-0.95) (eFigure 5 in the Supplement). Body mass index at older ages was not associated with hormone receptor-negative breast cancer risk. In analyses by intrinsic breast cancer subtype (Figure 3) , the nonluminal (ER-negative and PR-negative) subtype was inversely associated with BMI at ages 18 to 24 (HR, 0.86; 95% CI, 0.77-0.96) and 45 to 54 years (HR, 0.90; 95% CI, 0.84-0.98), but not with BMI at ages 25 to 34 and 35 to 44 years. No association of BMI at 25 years or older with triple-negative breast cancer or of BMI at 35 years or older with ERBB2/HER2enriched breast cancer was found.
Hazard ratios per 5.0-U difference in BMI were not significantly different between strata of most risk factors for breast cancer, including race/ethnicity (for BMI at ages 18 to 24 years: HR for black women, 0.84 [95% CI, 0.76-0.93]; HR for Asian women, 0.69 [95% CI, 0.40-1.18]; and HR for white women, 0.73 [95% CI, 0.70-0.77]; P = .08 for interaction) (eFigure 6 and eTable 6 in the Supplement). Hazard ratios were greater for never users compared with than ever users of oral contraceptives (at baseline for most studies) for BMI at ages 18 to 24 years (HR, 0.68 [95% CI, 0.61-0.76] vs 0.79 [95% CI, 0.75-0.83]; P = .02 for interaction) and ages 35 to 44 (HR, 0.81 [95% CI, 0.77-0.86] vs 0.88 [95% CI, 0.86-0.91]; P = .009 for interaction). The HR was also greater for nulliparous than parous women (HR, 0.79 [95% CI, 0.73-0.87] vs 0.88 [95% CI, 0.84-0.93]; P = .03 for interaction) for BMI at ages 25 to 34 years. Results were not materially affected in the sensitivity analyses (eTables 7-9 in the Supplement) except for those shown in Figure 1 .
Discussion
In this large prospective analysis investigating the association between adiposity and breast cancer risk in premenopausal women, we analyzed relative risk by BMI in a larger number of categories than possible in previous studies, re-vealing a 4.2-fold risk gradient between women who were underweight vs obese at ages 18 to 24 years and a 1.9-to 2.5-fold risk gradient between these BMI categories at later ages. We demonstrated that the inverse associations apply to the entire distribution of BMI, with risk variations evident even among women in the nonoverweight range of BMI. The observed inverse associations are unlikely to be attributable to bias, given that they were present in multiple studies and across strata of birth cohort and risk factors for breast cancer. Too few women died during follow-up (3.3% of women with a BMI≥35.0 vs 1.7% with BMI of 18.5-24.9) to explain the inverse associations for death as a competing risk. Our results are also supported as causal rather than artifactual by a mendelian randomization study 29 reporting genetically predicted BMI to be inversely associated with breast cancer risk.
The stronger inverse associations of risk with BMI at younger than older ages suggest that adiposity in young adulthood or earlier, if adiposity at approximately 20 years of age is a proxy marker for adiposity in childhood, is the critical factor. No cohorts in our collaboration had information on BMI at younger than 18 years, but published analyses of subjective body size compared with peers at these ages [7] [8] [9] have found strong inverse associations with premenopausal and postmenopausal breast cancer risk.
Our estimated 12% to 23% reduction in premenopausal breast cancer risk per 5.0-U difference in BMI depending on age is substantially stronger than that from meta-analyses, [3] [4] [5] 15, 16 which have reported 5% to 9% reductions among women overall without analysis by age at BMI, and a study reporting a 10% reduction using measured BMI at ages 16 to 19 years. 14 We observed that associations of BMI and breast cancer risk did not depend on attained age. We found no previous analyses by premenopausal attained age, but risk reductions with increased early-life BMI have been reported to continue after menopause. 7, 8 The associations of BMI with risk also did not appear to be appreciably modified by risk factors for breast cancer later in life, with the possible exception of nulliparity and oral contraceptive use.
The stronger associations of BMI at ages 25 to 44 years for in situ than for invasive breast cancer might reflect typespecific etiology or the association for in situ cancer being in part attributable to an association of body size with breast screening attendance. However, we found no evidence for this association, given that percentages of in situ cancer were similar across BMI groups.
No previous analyses of hormone receptor statusspecific breast cancer by BMI assessed at different premenopausal ages have been performed, to our knowledge. We found that hormone receptor-positive breast cancer was associated with BMI at all ages and that hormone receptor-negative breast cancer overall was associated with BMI at ages 18 to 24 years, but not consistently associated with BMI at later ages; metaanalyses of ER-and PR-negative tumors 15,17 have found no association, based on age at recruitment. The absence of an association of triple-negative breast cancer with BMI at 25 years or older in our analysis is contrary to previous reports 18,19 indicating an increased risk of this tumor type with obesity; however, these reports were based on case-control studies 18 and a pooled analysis of women younger than 50 years based on studies of mixed design 19 and therefore are subject to potential biases that are of less concern in prospective cohorts. We observed that ERBB2/HER2-enriched breast cancer was associated with BMI at 35 years or younger but not at later ages; the Nurses' Health Study, included in this analysis, previously reported a strong association with BMI at 18 years of age, 7 but we are not aware of studies investigating the association with later premenopausal ages.
Obesity has many adverse effects on general health, 30 and we do not advocate weight gain as a preventative measure against premenopausal breast cancer. However, understanding the mechanistic action underlying the inverse association of premenopausal adiposity with breast cancer risk could potentially identify modifiable pathways. Because the association with BMI at ages 18 to 24 years is significant for ER-positive and ER-negative tumors, hormonal and nonhormonal mechanisms might be involved. Breast tissue is particularly susceptible to carcinogens between menarche and first childbirth, 31 and the extent of this susceptibility may be influenced by childhood adiposity. Increased adiposity has a strong association with early pubertal onset but also slower pubertal tempo, 32 including slower peak growth, 33 and rapid adolescent growth has been associated with increased breast can- cer risk. 34 The estrogenic effects of being overweight in childhood, when adipose tissue is the major site of estrogen release, have been proposed to induce early breast differentiation or to increase the expression of tumor suppressor genes. 35 Being underweight during adolescence, in contrast, might result in immature differentiation due to lack of breast fat and/or low levels of ovarian hormones during breast development. 36 Early-adulthood adiposity is associated with intermediate markers of breast cancer risk, such as benign breast disease, 37 mammographic density, 38 and insulinlike growth factor 1 levels. 39 Greater mammographic density has a positive association with breast cancer risk, 40 and a more endomorphic somatotype in childhood and early adulthood is associated with lower mammographic density throughout adulthood. 38 In the Nurses' Health Study, 41 82% of the association of BMI at 18 years of age with breast cancer risk was explained by mammographic density, and breast density may be an intermediate factor in the biological pathway for breast cancer development. However, the mechanism of how density affects risk is not well understood, and the amount of nondense (ie, fatty) tissue, with which BMI is strongly correlated, is also inversely associated with breast cancer risk, independently of percentage density. 40 Early-life body size might also affect long-term insulinlike growth factor 1 levels implicated in breast cancer risk, 42 given that plasma insulinlike growth factor 1 levels at ages 32 to 70 years were reported to be 14% lower in women who were overweight compared with those who were lean at age 18 years. 39 The inverse association of BMI in premenopausal women 25 years or older with predominantly hormone receptorpositive rather than hormone receptor-negative breast cancer implies a hormonal mechanism. Estrogen synthesis, through the aromatase enzyme in subcutaneous fat, represents about 5% of total estradiol synthesis in premenopausal women, but with extreme obesity, negative feedback in the hypothalamic-pituitary-axis can lead to switch off of normal ovarian function and be reflected in amenorrhea. 43 Irregular menstrual or fewer ovulatory cycles have therefore been suggested as possible explanations for the inverse association, 44 but this suggestion has not been supported by studies that could adjust for menstrual cycle pattern. 9-11 However, BMI-related differences in sex-hormone profile may contribute to the inverse association of BMI and breast cancer risk. A study 45 reported that premenopausal women with higher BMI had lower estradiol, total testosterone, sex hormone-binding globulin, and progesterone levels but greater free testosterone levels than premenopausal women with lower BMI. Positive associations of premenopausal breast cancer risk have been reported with estradiol 46-49 and testosterone levels, [46] [47] [48] 50, 51 possibly stronger for ER-positive and/or PR-positive breast cancer, 47 but studies have been inconsistent. Studies investigating endogenous progesterone levels, 46,47,49-51 however, have not found associations with breast cancer risk. Circulating levels of leptin, a peptide hormone produced primarily by adipocytes that is overexpressed in breast cancer, were also associated with reduced premenopausal breast cancer risk in a prospective study, although not independently from BMI. 52
Strengths and Limitations
The strengths of this collaboration are its large number of cases, providing precise estimates of relative risk by age at adiposity and allowing for stratified and breast cancer subtypespecific analyses. All contributing studies were prospective, and most had multiple follow-up rounds, facilitating determination of menopausal status and time-updated covariate information.
However, the use of BMI has its limitations in that women with the same BMI can have different body fat distributions and overall body fat levels. 53 Body mass index was recalled for early adulthood, but a good correlation (r = 0.87) has been reported between recalled and measured weight at 18 years of age. 54 Current weight was usually self-reported, but in the Sister Study, 55 66% of women accurately reported their current weight within 1.35 kg, and underweight women tended to overreport and obese women tended to underreport, although rarely by more than 10%. If such misclassification applied to all studies, we might have slightly overestimated the trends but not to a sufficient degree to account for them fully. On the other hand, random misclassification would have led to attenuated effect sizes. Study-specific differences in method of assessment and cut points for hormone receptor and ERBB2/ HER2 status of breast cancer, given that these data were frequently obtained from medical records, may have led to differential classification of the tumor types between studies, potentially leading to underestimation of relative risks. More than 1000 breast cancer cases occurred in black women, allowing for stable estimation of relative risks in that population; results were similar to results from white women. However, we had insufficient statistical power to address the hypothesis that associations might be weaker or absent in Asian populations. 12, 13, 16, 56 
Conclusions
The results of our study suggest that increased BMI is inversely associated with the risk of breast cancer diagnosis before menopause, to a greater magnitude than suggested in previous analyses, and with the strongest associations for BMI at young ages. The association with BMI in early adulthood is universal across strata of other risk factors and across breast cancer subtypes. Understanding the biological mechanism underlying this association could have important implications for breast cancer prevention. (2):500-508.
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Body-mass index, age and premenopausal breast cancer risk:
A prospective analysis of 758,592 women (2) breast cancer with known ER, PR and HER2 status as endpoint (3) excluding subjects with weight assessed less than three years postpartum (4) strictly known premenopausal time only (5) 
Supplementary methods and results

The collaboration
Full details of the Premenopausal Breast Cancer Collaborative Group have been published elsewhere. 1 Individual-level data were pooled from 19 prospective cohorts with 100 breast cancer cases diagnosed before age 55 years, with the collaboration facilitated by the National Cancer Institute Cohort Consortium. Data were harmonised to a common template for 1-16 questionnaire rounds per study; all studies had at least two rounds except for the European Prospective Investigation into Cancer and Nutrition (EPIC) study, the Canadian Study of Diet, Lifestyle and Health (CSDLH), and HUNT2 for which only the baseline questionnaire was available. One study (CSDLH) provided data for a case-cohort subset; all the others provided data for the full cohort. Seventeen studies provided information on incident invasive and in-situ breast cancer and two (HUNT2 and Canadian Study of Diet, Lifestyle, and Health, CLDLH) on invasive breast cancer only.The pooled dataset was used to construct a dataset to investigate the endpoint of premenopausal breast cancer.
Derivation of age at menopause and premenopausal follow-up time
All cohorts collected information on menopausal status of participants at one or more questionnaire rounds. Participants were asked whether they had had any menstrual periods during the previous 6 or 12 months, depending on study, and/or whether they believed their periods had stopped permanently. Participants were asked about the age at their last period and the reason their periods stopped. We used this information to construct premenopausal follow-up time for analysis. Age at menopause was computed for each participant based on (i) reported age at menopause or, if age was missing, (ii) age first known postmenopausal if under age 50, (iii) age last known premenopausal if over age 50 or (iv) age 50 if no information was provided. When a hysterectomy was reported as reason for the menopause follow-up was censored at the reported age of the procedure. Since women with breast cancer often become postmenopausal due to their treatment and breast cancers diagnosed in the year of their menopause could be considered aetiologically premenopausal, we lagged reported menopausal ages (subjects under i) for all women by +1 year, i.e. the year during which they reported that they had become postmenopausal was analysed as premenopausal follow-up time. As a sensitivity analysis, we repeated the main analyses including only known premenopausal follow-up time up to the age at reported menopause (subjects under i) or, if age at menopause was missing, the age at the last questionnaire when the participant reported she was premenopausal (ii and iii).
Computation of BMI at various ages
We used data on current weight at the time of questionnaire completion and on recalled weight at ages before questionnaire completion, to construct variables for weight within the age ranges 18-24, 25-34, 35-44, 45-54 years. None of the studies had information to calculate BMI at ages younger than 18 years. Most weights at ages 18-24 years were retrospectively reported (most often for ages 18-21) but a minority were concurrently reported by subjects who were recruited at ages 18-24 years. At ages 25-34, 35-44 and 45-54, the majority of weights were concurrently reported. When weights were assessed on multiple occasions within an age category we used the earliest concurrent weight or otherwise the retrospectively reported weight relative to the youngest age within the age group. We recoded the following extreme values to missing based on visual inspection of histograms and percentile distributions: height (<130 or >195 cm), weight (<30, >200 kg), BMI (<15, >49 kg/m 2 ) and weights that arose from BMI values outside this range. In pooled analyses, BMI was categorised according to World Health Organization definitions 2 as severe/moderate thinness (<17 kg/m 2 ), mild thinness (17-18.5 kg/m 2 ), normal range (18.5-22.9 and 23.0-24.9 kg/m 2 ), overweight (25-27.4 and 27.5-29.9 kg/m 2 ), obese Class I (30-32.4 and 32.5-34.9 kg/m 2 ) and obese Class II/III (35 kg/m 2 ). Where numbers in the extreme categories were small or to obtain study-specific, stratum-specific or tumour type-specific estimates we combined categories to obtain stable estimates. For each age-specific BMI investigated, studies with less than 10 cases among subjects with known BMI were excluded from the model to improve convergence.
Clinicopathological surrogate definition of breast cancer intrinsic subtypes
Immunohistochemistry data on estrogen (ER) and progesterone receptor (PR) status, as well as data on Human epidermal growth factor receptor-2 (HER2) oncogene expression was collected from the centres. Given the absence of data on the proliferation marker KI-67, we adapted clinicopathological surrogate definitions of luminal A and luminal Blike intrinsic breast cancer subtypes proposed by the St Gallen Expert Consensus. 3 We classified all ER+PR+HER2breast cancer as luminal A-like, ER+PR-HER2-and ER-PR+HER2-as luminal B-like HER2 negative, [ER+/PR+]HER2+ to luminal B-like HER2 positive, ER+PR-and ER-PR+ with HER2 status unknown as luminal B unclassified, ER+ or PR+ with other markers unknown as unclassified luminal, ER-PR-HER2-as triple-negative, ER-PR-HER2+ as HER2 enriched, ER-with PR unknown or PR-with ER unknown regardless of HER2 status as unclassified.
Statistical methods
Analyses were conducted using Stata 14.2 software 4 . BMI was analysed separately as a categorical and as a continuous variable (per 5 kg/m 2 ), assuming a log-linear dose-response relationship, the validity of which was checked using 5-knot restricted cubic spline models. 5 Hazard ratios (HR) as estimates of relative risk of breast cancer were obtained from Cox proportional hazards models 6 with attained age as the underlying time-scale. All analyses were conducted using Stata 14.2 software 4 . Pooled analyses were adjusted for attained age (implicit in the Cox model) and cohort (including country within EPIC). In multivariable-adjusted models we additionally adjusted for year of birth (<1930, 1930-9, 1940-9, 1950-9, 1960-9, 1970-9, to 1980) , age at menarche (7) (8) (9) (10) (11) (12) (13) , 14 years, not known), age at first birth (<25, 25-34, 35 years, not known or not applicable), time since last birth (<5, 5-9, 10-14, 15-19, 20-24, 25-29 , 30 years, not known or not applicable), parity (0, 1, 2, 3, parous but not known) and family history of breast cancer (yes, no, not known).
Hazard ratios for breast cancer with respect to BMI were near-identical in age-and cohort-adjusted models compared with models additionally (fully) adjusted for other breast cancer risk factors. Fully adjusted models are therefore presented in the main paper. In models additionally adjusted for BMI at age 18-24, BMI at this age was coded as <18. 5, 18.5-22.9, 23.0-24.9, 25.0-27.4, 27.5-29.9 , 30 kg/m 2 ). Height was included as a continuous variable in models additionally adjusted for adult height. Covariate information was time-updated, where possible, with information from follow-up questionnaires for all pregnancy-related variables and family history of breast cancer. Subjects with missing covariate values were included in the analyses by fitting a category for the missing value. In order to include the case-cohort study (CSDLH) in the pooled data set, we included Barlow weights 7 for CSDLH corresponding to a sampling fraction of 5.0 percent as an off-set in the model. We also applied Barlow weights with a sampling fraction of (effectively) 1.0 to all other cohorts using the stcasecoh command in Stata 14.2 software 4 , which did not affect the results for those cohorts, but facilitated ease of obtaining results from a single pooled dataset.
Sensitivity analyses
In sensitivity analyses, we repeated the analyses (i) for BMI at ages 25 onwards adjusting for BMI at age 18-24 years (Figure 1 ) (ii) for BMI at ages 25 onwards restricted to individuals for whom BMI at ages 18-24 was also available (eTable 2) (iii) excluding subjects whose weight was recalled or reported less than three years postpartum (eTable 7) (iv) restricting follow-up to person-time that was known to be, rather than assumed to be, premenopausal (eTable 7) (v) excluding the first two years of follow-up (eTable 7) (vi) restricting the endpoint to breast cancer with information on all of ER, PR and HER2 status (eTable 7) (vii) excluding one cohort at the time (eTable 8) (viii) additional adjustment for adult height (not shown) (vix) comparing with and without adjustment for polycystic ovary syndrome (PCOS), for centres with data on PCOS (not shown). 1900-1939 1940-1949 1950-1959 1960+ 
eTable 1: Study characteristics and numbers of premenopausal women with information on BMI, by cohort study
NYUWHS (c) - - - - - - - - RERF (d) - - - - - - - - SCHS (c) - - - - - - - - SIS (c) - - - - - - - - SMC
